Treating the metabolic syndrome

References

• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet365, 1415–1428 (2005).
   PubMed Web of Science ®Google Scholar
• Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care28, 1769–1778 (2005).
   PubMed Web of Science ®Google Scholar
• WHO. Definition, diagnosis and classification of diabetes and its complications. Part 1. In WHO, Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland CH (Tech. Resp. Ser. No. 99.2) (1999).
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet366, 1059–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American HeartAssociation/National Heart, Lung, and Blood Institute scientific statement. Circulation112(17), 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Williams K, Hunt KJ, Haffner SM. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care29, 625–630 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu S, St-Onge MP, Heshka S, Heymsfield SB. Lifestyle behaviours associated with lower risk of having the metabolic syndrome. Metabolism53, 1503–1511 (2004).
   PubMed Web of Science ®Google Scholar
• Webber LS, Bedimo-Rung AL. The obesity epidemic: incidence and prevalence. J. La State Med. Soc.157, S3–S11 (2005).
   PubMedGoogle Scholar
• Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD. Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults. The Amsterdam Growth and Health Longitudinal Study. Arch. Intern. Med.165, 42–48 (2005).
   PubMedGoogle Scholar
• Poobalan A, Aucott L, Smith WC et al. Effects of weight loss in overweight/obese individuals and long-term lipid outcomes – a systematic review. Obes. Rev.5, 43–50 (2004).
   PubMedGoogle Scholar
• Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF. Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann. Intern. Med.138, 383–389 (2003).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG et al; for the Finnish Diabetes Prevention Study Group. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med.34, 1343–1350 (2001).
   Google Scholar
• The Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346, 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care20, 537–544 (1997).
   PubMed Web of Science ®Google Scholar
• Lindstrom J, Ilanne-Parikka P, Peltonen M et al; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of Type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet368, 1673–1679 (2006).
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R et al; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med.142, 611–619 (2005).
   PubMed Web of Science ®Google Scholar
• Mann JI. Nutrition recommendations for the treatment and prevention of Type 2 diabetes and the metabolic syndrome: an evidenced-based review. Nutr. Rev.64, 422–427 (2006).
   PubMed Web of Science ®Google Scholar
• Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin. Nutr.23, 447–456 (2004).
   PubMed Web of Science ®Google Scholar
• Vessby B, Tengblad S, Lithell H. Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia37, 1044–1050 (1994).
   PubMed Web of Science ®Google Scholar
• Pan DA, Lillioja S, Milner MR et al. Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J. Clin. Invest.96, 2802–2808 (1995).
   PubMed Web of Science ®Google Scholar
• Vessby B, Unsitupa M, Hermansen K et al. KANWU Study. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study. Diabetologia44, 312–319 (2001).
   PubMed Web of Science ®Google Scholar
• Howard BV. Dietary fat as a risk factor for Type 2 diabetes. Ann. NY Acad. Sci.967, 324–328 (2002).
   PubMed Web of Science ®Google Scholar
• Ylonen K, Saloranta C, Kronberg-Kippila C, Groop L, Aro A, Virtanen SM; Botnia Dietary Study. Associations of dietary fiber with glucose metabolism in nondiabetic relatives of subjects with Type 2 diabetes: the Botnia Dietary Study. Diabetes Care26, 1979–1985 (2003).
   PubMed Web of Science ®Google Scholar
• Schulze MB, Liu S, Rimm EB, Manson JE, Willett WC, Hu FB. Glycemic index, glycemic load, and dietary fiber intake and incidence of Type 2 diabetes in younger and middle-aged women. Am. J. Clin. Nutr.80, 348–356 (2004).
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R; Third National Health and Nutrition Examination Survey. Alcohol consumption and the prevalence of the Metabolic Syndrome in the US: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care27, 2954–2959 (2004).
   PubMed Web of Science ®Google Scholar
• Lichtenstein AH, Appel LJ, Brands M et al. American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation114, 82–96 (2006).
   PubMed Web of Science ®Google Scholar
• Arif AA, Rohrer JE. Patterns of alcohol drinking and its association with obesity: data from the Third National Health and Nutrition Examination Survey, 1988–1994. BMC Public Health5, 126 (2005).
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Polychronopoulos E. The role of Mediterranean diet in the epidemiology of metabolic syndrome; converting epidemiology to clinical practice. Lipids Health Dis.4, 7 (2005).
   PubMedGoogle Scholar
• Katzmarzyk PT, Leon AS, Wilmore JH et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med. Sci. Sports Exerc.35, 1703–1709 (2003).
   PubMed Web of Science ®Google Scholar
• Pitsavos C, Panagiotakos DB, Chrysohoou C, Kavouras S, Stefanadis C. The associations between physical activity, inflammation, and coagulation markers, in people with metabolic syndrome: the ATTICA study. Eur. J. Cardiovasc. Prev. Rehabil.12, 151–158 (2005).
   PubMedGoogle Scholar
• Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab.86, 5755–5761 (2001).
   PubMed Web of Science ®Google Scholar
• Thompson PD, Buchner D, Pina IL et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the American Heart Association council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity). Circulation107, 3109–3116 (2003).
   PubMed Web of Science ®Google Scholar
• Ross R, Dagnone, D, Jones PJ et al. Reduction in obesity and related co-morbid conditions after diet-induced weight loss or exercise-induced weight loss in men. Ann. Intern. Med.133, 92–103 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Is insulin resistance the cause of the metabolic syndrome? Ann. Med.38, 42–51 (2006).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care27, 2444–2449 (2004).
   PubMed Web of Science ®Google Scholar
• Bianchi C, Penno G, Malloggi L et al. Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with Type 2 diabetes and metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. In press (2006).
   Google Scholar
• Sherwin RS, Anderson RM, Buse JB et al. American Diabetes Association. The prevention or delay of Type 2 diabetes. Diabetes Care26(Suppl. 1), S62–S69 (2003).
   PubMed Web of Science ®Google Scholar
• The Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care26, 977–980 (2003).
   PubMed Web of Science ®Google Scholar
• Prevention of Type 2 diabetes with Troglitazone in the Diabetes Prevention Program. The Diabetes Prevention Program Research Group. Diabetes54, 1150–1156 (2005).
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic B-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes51, 2796–2803 (2002).
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes55, 517–522 (2006).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Bosch J et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368, 1096–1105 (2006).
   PubMed Web of Science ®Google Scholar
• Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in Type 2 diabetes mellitus: a systematic review. J. Intern. Med.256, 1–14 (2004).
   PubMed Web of Science ®Google Scholar
• Brame L, Verma S, Anderson T, Lteif A, Mather K. Insulin resistance as a therapeutic target for improved endothelial function: metformin. Curr. Drug Targets Cardiovasc. Haematol. Disord.4, 53–63 (2004).
   PubMedGoogle Scholar
• Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med.258, 250–256 (2005).
   PubMed Web of Science ®Google Scholar
• Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Technol. Therapeut.2, 259–272 (2000).
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with Type 2 diabetes. Lancet352, 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferators-activated receptorγ agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J. Am. Coll. Cardiol.42, 1757–1763 (2003).
   PubMed Web of Science ®Google Scholar
• Phillips SA, Ciaraldi TP, Kong AP et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes52, 667–674 (2003).
   PubMed Web of Science ®Google Scholar
• Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with Type 2 diabetes. Diabetes Care27, 2654–2660 (2004).
   PubMed Web of Science ®Google Scholar
• Nishio K, Sakurai M, Kusuyama T et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with Type 2 diabetes. Diabetes Care29, 101–106 (2006).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al; PROactive investigators. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet366, 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am. J. Med. Sci.330, 326–335 (2005).
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355, 2297–2307 (2006).
   PubMed Web of Science ®Google Scholar
• Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR. Insulin resistance in hypertension and cardiovascular disease. Best Pract. Res. Clin. Endocrinol. Metab.20, 355–367 (2006).
   PubMed Web of Science ®Google Scholar
• Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin. Cornerstone8(Suppl. 1), S21–S27 (2006).
   Google Scholar
• Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care28, 2289–2304 (2005).
   PubMed Web of Science ®Google Scholar
• Penno G, Miccoli R, Pucci L, Del Prato S. The metabolic syndrome. Beyond the insulin resistance syndrome. Pharmacol. Res.53, 457–468 (2006).
   PubMed Web of Science ®Google Scholar
• Carr DB, Utzschneider KM, Hull RL et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes53, 2087–2094 (2004).
   PubMed Web of Science ®Google Scholar
• Schondorf T, Maiworm A, Emmison N, Forst T, Pfutzner A. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin. Lab.51, 489–494 (2005).
   PubMed Web of Science ®Google Scholar
• Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults – the evidence report. Natl Inst. Health Obes. Res.2(Suppl. 6), 51S–209S (1998).
   Google Scholar
• Grundy SM, Hansen B, Smith SC Jr et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/ American Diabetes Association conference on scientific issues related to management. Circulation109, 551–556 (2004).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Abate N, Chandalia M. Diet composition and the metabolic syndrome: what is the optimal fat intake? Am. J. Med.113, 255–295 (2002).
   PubMed Web of Science ®Google Scholar
• Blackwell J. Identification, evaluation, and treatment of overweight and obesity in adults. J. Am. Acad. Nurse Pract.14, 196–198 (2002).
   PubMedGoogle Scholar
• Silverstone T. Appetite suppressants. A review. Drugs43, 820–836 (1992).
   PubMed Web of Science ®Google Scholar
• Gardin JM, Schumacher D, Constantine G et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA283, 1703–1709 (2000).
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N. Engl. J. Med.343, 1826–1832 (2000).
   PubMed Web of Science ®Google Scholar
• Finer N. Sibutramine: its mode of action and efficacy. Int. J. Obes.26(Suppl. 4), S29–S33 (2002).
   Google Scholar
• Thearle M, Aronne LJ. Obesity and pharmacologic therapy. Endocrinol. Metab. Clin. North Am.32, 1005–1024 (2003).
   PubMed Web of Science ®Google Scholar
• Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord.27, 1437–1446 (2003).
   PubMed Web of Science ®Google Scholar
• James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet356, 2119–2125 (2000).
   PubMed Web of Science ®Google Scholar
• McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese Type 2 diabetic patients treated with metformin. Diabetes Care26, 125–131 (2003).
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch. Intern. Med.164, 994–1003 (2004).
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care27, 155–161 (2004).
   PubMed Web of Science ®Google Scholar
• Didangelos TP, Thanopoulou AK, Bousboulas SH et al. The ORLIstat and Cardiovascular risk profile in patients with metabolic syndrome and Type 2 DIAbetes (ORLICARDIA) Study. Curr. Med. Res. Opin.20, 1393–1401 (2004).
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr. Med. Res. Opin.21, 1997–2006 (2005).
   PubMed Web of Science ®Google Scholar
• Black SC. Cannabinoid receptor antagonists and obesity. Curr. Opin. Investig. Drugs5, 389–394 (2004).
   PubMedGoogle Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA295, 761–775 (2006).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet365, 1389–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L, for the RIO-Lipids study group. Effect of rimonabant on body weight and the metabolic syndrome in overweight patients. N. Engl. J. Med.353, 2121–2134 (2005).
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet368, 1660–1672 (2006).
   PubMed Web of Science ®Google Scholar
• Colquitt J, Clegg A, Loveman E, Royle P, Sidhu MK. Surgery for morbid obesity. Cochrane Database Syst. Rev.4, CD003641 (2006).
   Google Scholar
• Wei-Jei L, Ming-Te H, Weu W, Ching-Mei L, Tai-Chi C, I-Ru L. Effects of obesity surgery on the metabolic syndrome. Arch. Surg.139, 1088–1092 (2004).
   PubMedGoogle Scholar
• Iribarren C, Go AS, Husson G et al. Metabolic syndrome and early-onset coronary artery disease: is the whole greater than its parts? J. Am. Coll. Cardiol.48, 1800–1807 (2006).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br. Med. J.248, 1152–1157 (1989).
   Google Scholar
• Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care14, 203–209 (1991).
   PubMed Web of Science ®Google Scholar
• Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am. J. Cardiol.77, 12b–16b (1996).
   Web of Science ®Google Scholar
• Uzunlulu M, Oguz A, Yorulmaz E. The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. Int. Heart J.47, 421–430 (2006).
   PubMed Web of Science ®Google Scholar
• Lithell HO. Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. J. Hypertens. Suppl15, S39–S42 (1997).
   Google Scholar
• Whelton PK, Barzilay J, Cushman WC et al; ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of Type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.165, 1401–1409 (2005).
   PubMed Web of Science ®Google Scholar
• Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab. Res. Rev.18(Suppl. 3), S82–S85 (2002).
   Google Scholar
• Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML; EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur. Heart J.26, 1369–1378 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Rice MM, Jablonski K et al; Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation114, 26–31 (2006).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am. Heart J.148, 747–754 (2004).
   PubMed Web of Science ®Google Scholar
• Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr. Pharm. Des.11, 1291–1300 (2005).
   PubMed Web of Science ®Google Scholar
• Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation110, 1013–1020 (2004).
   PubMed Web of Science ®Google Scholar
• Lonn E. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr. Atheroscler. Rep.4, 363–372 (2002).
   PubMedGoogle Scholar
• Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ. Int. J. Biochem. Cell Biol.38, 766–781 (2006).
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet355, 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA286, 1882–1885 (2001).
   PubMed Web of Science ®Google Scholar
• Bosch J, Yusuf S, Gerstein HC et al; DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med.355, 1551–1562 (2006).
   PubMed Web of Science ®Google Scholar
• Pyorala K, Ballantyne CM, Gumbiner B et al; Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care27, 1735–1740 (2004).
   PubMed Web of Science ®Google Scholar
• Kamalesh M, Rao R, Sawada S, Friend A, Schellhase E, Evans T. Effect of 80 mg/day simvastatin therapy on cardiovascular outcomes in adults with versus without metabolic syndrome. Am. J. Cardiol.97, 1487–1489 (2006).
   PubMed Web of Science ®Google Scholar
• Deedwania P, Barter P, Carmena R et al; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet368, 919–928 (2006).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, Hunninghake DB et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am. Heart J.146, 862–869 (2003).
   PubMed Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am. Heart J.147, 705–712 (2004).
   PubMed Web of Science ®Google Scholar
• Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes. Metab.7, 430–438 (2005).
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF, Ballantyne CM, Sarti C et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur. Heart J.26, 2664–2672 (2005).
   PubMed Web of Science ®Google Scholar
• Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab. Vasc. Dis. Res.3, 93–102 (2006).
   PubMedGoogle Scholar
• Avogaro A, Miola M, Favaro A et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in Type 2 diabetic patients. Eur. J. Clin. Invest.31, 603–609 (2001).
   PubMed Web of Science ®Google Scholar
• Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care28, 1419–1424 (2005).
   PubMed Web of Science ®Google Scholar
• Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation92, 1779–1785 (1995).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med.341, 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366, 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med.162, 2597–2604 (2002).
   PubMed Web of Science ®Google Scholar
• Robins SJ, Rubins HB, Faas FH et al. Insulin resistance and cardiovascular events with low HDL cholesterol. Diabetes Care26, 1513–1517 (2003).
   PubMed Web of Science ®Google Scholar
• Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol.95, 254–257 (2005).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, McGovern ME et al; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med.162, 1568–1576 (2002).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive proteion, the metabolic syndrome, and the risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation107, 391–397 (2003).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation109, 2818–2825 (2004).
   PubMed Web of Science ®Google Scholar
• Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation109(Suppl. 1), II2–II10 (2004).
   PubMedGoogle Scholar
• van Dielen FM, Buurman WA, Hadfoune M, Nijhuis J, Greve JW. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J. Clin. Endocrinol. Metab.89, 4062–4068 (2004).
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-peactive protein levels. Circulation103, 1933–1935 (2001).
   PubMed Web of Science ®Google Scholar
• Schieffer B, Bunte C, Witte J et al. Comparative effects of AT1-antagonism and angiotensinconverting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J. Am. Coll. Cardiol.44, 362–368 (2004).
   PubMed Web of Science ®Google Scholar
• Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet. Med.21, 810–817 (2004).
   PubMed Web of Science ®Google Scholar
• Machado AP. Metabolic syndrome, atherosclerosis and thrombogenic risk. Rev. Port. Cardiol.25, 173–178 (2006).
   PubMedGoogle Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J.324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Esposito K, Marfella R, Ciotola M et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA292, 1440–1446 (2004).
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med.351, 1106–1118 (2004).
   PubMed Web of Science ®Google Scholar
• Sola S, Mir MQ, Cheema FA et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation111, 343–348 (2005).
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature444, 881–887 (2006).
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med.348, 383–393 (2003).
   PubMed Web of Science ®Google Scholar